Jupiter Neurosciences partners with Aquanova on health products

JUPITER, Fla. - Jupiter Neurosciences, Inc. (NASDAQ: JUNS), a clinical-stage pharmaceutical company currently valued at $19.32 million, has announced a strategic partnership with Aquanova AG, a technology firm specializing in bioavailability, to develop nutritional products aimed at longevity and healthspan. According to InvestingPro data, the stock has experienced significant volatility, trading near its 52-week low of $0.55. The collaboration, building on an eight-year relationship in developing Jupiter’s lead product JOTROL™, a resveratrol-based formulation, is set to launch its first three consumer products in Q3 2025.

The upcoming Direct-to-Consumer (DTC) products focus on the concept of "Beauty from Within," incorporating scientific research to support health and longevity. JOTROL™, which is currently advancing toward a Phase IIa trial for Parkinson’s Disease, has shown potential in treating central nervous system (CNS) disorders like Alzheimer’s and Parkinson’s through preclinical and clinical data.

Christer Rosén, Chairman & CEO of Jupiter Neurosciences, emphasized the strategic expansion into the consumer market as a response to the increasing demand for science-backed health solutions. The company’s pharmaceutical-driven approach and the clinical foundation of JOTROL™ are cited as key advantages for delivering effective consumer products.

Aquanova’s CEO, Frank Behnam, highlighted the importance of their NovaSOL™ technology in overcoming resveratrol’s bioavailability and absorption issues, ensuring the ingredient reaches effective levels in the body safely.

Jupiter plans to launch the products through a new wholly owned subsidiary, providing shareholders with the opportunity to participate in the commercial success of the venture. Revenue from this subsidiary is expected to support Jupiter’s ongoing pharmaceutical trials. InvestingPro subscribers can access 13 additional ProTips and comprehensive financial metrics to better evaluate the company’s potential, including detailed analysis of its debt levels and profit margins.

This announcement is based on a press release statement and is intended to inform about the partnership and product launch plans. Jupiter Neurosciences is known for its focus on neuroinflammation and CNS disorders, while Aquanova AG has established itself as a leader in enhancing the bioavailability of natural compounds through its NovaSOL® technology.

In other recent news, Jupiter Neurosciences, Inc. has announced several strategic developments aimed at advancing its clinical and commercial initiatives. The company plans to launch a Direct-to-Consumer product line in 2025, which is expected to generate revenue while ongoing clinical trials continue. This initiative is part of a broader strategy to diversify its business model and provide immediate cash flow. Jupiter Neurosciences has secured partnerships with Catalent (NYSE:CTLT) Pharma Solutions and Zina Biopharmaceuticals to advance a Phase 2a clinical trial of its resveratrol-based therapeutic, JOTROL™, targeting Parkinson’s disease. The trial will assess the safety, tolerability, and pharmacokinetics/pharmacodynamics of JOTROL™, which has shown significantly enhanced bioavailability in previous studies.

Additionally, the company has refocused its efforts on exploring the NLRP3 inflammasome in upcoming clinical trials, which could lead to new treatments for neurodegenerative and aging-related conditions. Jupiter Neurosciences is also looking to expand globally, with plans to build licensing and commercialization partnerships in Asia. In financial news, the company has revised the compensation agreement for its Chief Financial Officer, with a new annual fee set at $240,000 for 2025. These recent developments reflect Jupiter’s commitment to addressing unmet medical needs in neurodegenerative diseases and its strategic approach to financial and clinical growth.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.